Explore

Rapid Read Rapid Read
Moderna Initiates Human Trials for Ebola Vaccine Amid Congo's Escalating Outbreak

Moderna Initiates Human Trials for Ebola Vaccine Amid Congo's Escalating Outbreak

Moderna has commenced human trials for a vaccine targeting the Bundibugyo strain of the Ebola virus, as the Democratic Republic of the Congo faces its second-largest Ebola outbreak in history. The outbreak, primarily concentrated in the eastern Ituri province, has recorded over 3,800 cases and 1,700 deaths. The rapid spread of the virus is attributed to community transmission, with contact tracing proving ineffective. The vaccine trials, conducted in Canada, involve around 80 volunteers and aim to assess the vaccine's safety and immune response. This initiative is part of a broader effort by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccines against emerging infectious diseases.
Rapid Read Rapid Read
Health Canada Approves Moderna's mRNA Vaccine Trial Amid Congo Ebola Outbreak

Health Canada Approves Moderna's mRNA Vaccine Trial Amid Congo Ebola Outbreak

Health Canada has authorized Moderna to conduct a Phase 1 clinical trial for a vaccine targeting the Bundibugyo strain of the Ebola virus, which is currently causing a significant outbreak in the Democratic Republic of the Congo. This outbreak has resulted in over 3,800 confirmed cases and more than 1,700 deaths. The trial will take place at three sites in Canada and will involve approximately 80 participants. The vaccine uses mRNA technology, similar to that used in COVID-19 vaccines. This development comes as the outbreak continues to spread across multiple provinces in Congo, with health officials struggling to contain it due to violence and mistrust in affected areas.
Rapid Read Rapid Read
Health Canada Approves Clinical Trial for Moderna's mRNA Ebola Vaccine Amidst Outbreak

Health Canada Approves Clinical Trial for Moderna's mRNA Ebola Vaccine Amidst Outbreak

Health Canada has authorized Moderna to conduct a Phase I clinical trial for an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus, which is currently causing a significant outbreak in the Democratic Republic of the Congo. This approval makes Canada the second country, after the U.K., to authorize such a trial. The trial will assess the immune response of participants to the vaccine, which does not involve injecting the virus itself. This development is part of a broader effort to address the lack of licensed vaccines for this particular strain of Ebola.
Rapid Read Rapid Read
Health Canada Authorizes Clinical Trial for Ebola Vaccine by Moderna

Health Canada Authorizes Clinical Trial for Ebola Vaccine by Moderna

Health Canada has approved a Phase I clinical trial for Moderna's mRNA vaccine targeting the Bundibugyo strain of Ebola. This strain is responsible for a significant outbreak in the Democratic Republic of the Congo. The trial will assess the vaccine's safety, dosage, and side effects in healthy participants. Canada is the second country to authorize such a trial, following the U.K. The trial is part of a broader effort to develop a vaccine for this strain, which currently has no approved treatment.
Reuters Reuters
Why Congo's Ebola outbreak is spreading faster than previous epidemics

Why Congo's Ebola outbreak is spreading faster than previous epidemics

By Clement Bonnerot and Jessica Donati DAKAR, Aug 5 (Reuters) - The Ebola epidemic in Democratic Republic of Congo is on track to surpass 4,000 cases this week and has been described as the fastest spreading on record since it was officially declared in May.  
Rapid Read Rapid Read
Moderna Initiates Phase 1 Clinical Trial for Ebola Vaccine Targeting DRC Strain

Moderna Initiates Phase 1 Clinical Trial for Ebola Vaccine Targeting DRC Strain

Moderna has commenced a Phase 1 clinical trial for an Ebola vaccine targeting the Bundibugyo strain, currently affecting the Democratic Republic of the Congo (DRC). The trial, conducted in Canada, will assess the vaccine's safety and tolerability using Moderna's mRNA platform, previously utilized for COVID-19 vaccines. The trial involves 80 participants and is supported by the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million for preclinical testing and the trial. The vaccine aims to address the ongoing Ebola outbreak in the DRC, which has resulted in over 3,700 cases and 1,600 deaths.
AP News AP News
Dozens of health workers at epicenter of Congo’s Ebola outbreak protest lack of payment

Dozens of health workers at epicenter of Congo’s Ebola outbreak protest lack of payment

Health workers at the epicenter of Congo’s Ebola outbreak are protesting over unpaid wages
AP News AP News
Congo Ebola health workers protest unpaid wages, disrupting response as deaths top 1,800

Congo Ebola health workers protest unpaid wages, disrupting response as deaths top 1,800

Health workers at the epicenter of Congo’s Ebola outbreak are protesting over unpaid wages
Rapid Read Rapid Read
Moderna Advances mRNA Vaccine for Ebola with Phase I Trial Launch

Moderna Advances mRNA Vaccine for Ebola with Phase I Trial Launch

Moderna has initiated a Phase I clinical trial for its mRNA-1469 vaccine, targeting the Bundibugyo strain of the Ebola virus. This development follows authorization from Health Canada, marking a significant step in combating the ongoing Ebola outbreak in the Democratic Republic of the Congo. The trial is part of a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million to support the vaccine's development. The Bundibugyo strain has been responsible for over 3,000 confirmed cases and more than 1,400 deaths. Moderna's CEO, Stéphane Bancel, emphasized the importance of this milestone, noting the lack of an approved vaccine for this strain. The collaboration aims to rapidly advance to larger Phase II and III trials if initial results are promising.
AP News AP News
WHO chief visits Congo to support Ebola efforts as some workers strike over pay

WHO chief visits Congo to support Ebola efforts as some workers strike over pay

The head of the World Health Organization has arrived in Congo as the Ebola outbreak spreads at an alarming rate
Rapid Read Rapid Read
Moderna Begins Ebola Vaccine Trial as FDA Decision on Flu Shot Looms

Moderna Begins Ebola Vaccine Trial as FDA Decision on Flu Shot Looms

Moderna has initiated a Phase 1 clinical trial for its experimental Ebola vaccine targeting the Bundibugyo strain. The trial, conducted in Canada, will assess the vaccine's safety and immune response in 80 adults. This development comes as the U.S. FDA is set to decide on Moderna's seasonal influenza vaccine for adults aged 50 and older. The Ebola vaccine trial is supported by the Coalition for Epidemic Preparedness Innovations, which has committed up to $50 million for early development.
Reuters Reuters
Moderna begins first human trial of Bundibugyo Ebola vaccine

Moderna begins first human trial of Bundibugyo Ebola vaccine

Aug 4 (Reuters) - Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and currently has no approved vaccine.